April 18, 2021, 11:21 p.m. EDT

Growth Hormone Deficiency Market Growth Analysis, Share, Revenue and Forecast 2028

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

Apr 18, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Growth Hormone Deficiency Market: Global Demand Analysis & Opportunity Outlook 2028" which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution channel,  and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis, and Porter's five force model.

The growth hormone in the human body is responsible for increasing the height during childhood, raising calcium retention levels, strengthening, and improving bone mineralization. Without these, children and adults can experience underdeveloped growth and a lot of other physical and mental issues. Growth hormone deficiency (GHD) in humans is initiated when the pituitary gland does not synthesize enough human growth hormonealso known as somatotropin.

The growth hormone deficiency market is expected to witness an attainable high CAGR during the forecast period, i.e., 2020-2028. The market is segmented by application, route of administration, distribution channel, and region. Among product applications, the Turner syndrome segment is projected to dominate the overall market owing to its risingoccurrences across the globe and enhanced awareness of Turner syndrome in the medical community.

Regionally, the growth hormone deficiency market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

Request Sample of This Strategic Report @ https://www.researchnester.com/sample-request-2683

The growth hormone deficiency market in the North-America region is expected to hold a major market share on account of the growing occurrence of growth hormone deficiency and Turner syndrome, affordability of expensive hormonal therapy, presence of well-established healthcare infrastructure, and growing R&D associated with growth hormones.

Europe is expected to be the second-largest market for growth hormone deficiency owing to factors such as rising government spending on healthcare infrastructure in the European countries and growing cases of growth hormone deficiencies among the population.

The Asia-Pacific region is estimated to witness the fastest growth during the forecast period owing to the increasing demand for growth hormone in the emerging countries, expansion in healthcare spending, infiltration of leading players into the market, growing population, and an increase in disposable income.

Risingprevalence of chronic diseasesglobally is expected to drive the market growth.

Prolonged diseases such as growth retardation, pituitary dysfunctions, complemented by changing lifestyle, the prevalence of other genetic disorders, prevalence of GHD in adults, and surge in compliance for growth hormone creations are the contributing factors driving the market growth globally.

Additionally, a rise in disposable income, a surge in healthcare expenditure in developing economies, initiatives by numerous government and private organizations to spread alertness for growth hormone deficiencies, and as well as awareness for human growth hormone treatment is estimated to drive the market growth.

Request For COVID-19 Impact Insights on This Report@ https://www.researchnester.com/ask-the-analyst/rep-id-2683

This report also provides the existing competitive scenario of some of the key players of the growth hormone deficiency market which includes company profiling of Teva Pharmaceuticals Industries Ltd. (tlv:TEVA), Ipsen Pharma Biotech SAS, Novartis AG (swx:NOVN), Pfizer, Inc. /zigman2/quotes/202877789/composite PFE -0.15% , F. Hoffmann-La Roche Ltd (swx:RO), Ferring B.V., Novo Nordisk A/S (cph:NOVO-B), Eli Lilly and Company /zigman2/quotes/200106384/composite LLY -0.46% , AnkeBio Co., Ltd, Merck KGaA (etr:MRK).

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates, and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided the right guidance at the right time is available through strategic minds. Our out of box thinking helps our clients to take wise decisions to avoid future uncertainties.

Contact Us

AJ Daniel
Email:  info@researchnester.com
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]

The post Growth Hormone Deficiency Market Growth Analysis, Share, Revenue and Forecast 2028 appeared first on America News Hour .


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

$ 40.05
-0.06 -0.15%
Volume: 15.62M
May 18, 2021 4:03p
P/E Ratio
Dividend Yield
Market Cap
$223.74 billion
Rev. per Employee
$ 194.63
-0.90 -0.46%
Volume: 2.34M
May 18, 2021 4:03p
P/E Ratio
Dividend Yield
Market Cap
$187.52 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.